Menu
Search
|

Menu

Close
X

Pulmatrix Inc PULM.OQ (NASDAQ Stock Exchange Global Market)

0.54 USD
-- (--)
As of Jul 13
chart
Previous Close 0.54
Open --
Volume --
3m Avg Volume 242,131
Today’s High --
Today’s Low --
52 Week High 2.67
52 Week Low 0.41
Shares Outstanding (mil) 41.93
Market Capitalization (mil) 23.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
FY15
2
EPS (USD)
FY18
-0.239
FY17
-0.927
FY16
-1.879
FY15
-1.875
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
47.24
8.07
Price to Book (MRQ)
vs sector
1.63
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
33.53
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-152.34
13.23
Return on Equity (TTM)
vs sector
-168.96
15.28

EXECUTIVE LEADERSHIP

Mark Iwicki
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Robert Clarke
Chief Executive Officer, Director, Since 2015
Salary: $220,635.00
Bonus: $115,500.00
William Duke
Chief Financial Officer, Since 2015
Salary: $160,385.00
Bonus: $91,250.00
David Hava
Chief Scientific Officer, Since 2012
Salary: $163,327.00
Bonus: $64,125.00
Jean Sung
Vice President - Pharmaceutical Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 390
LEXINGTON   MA   02421-7966

Phone: +1781.3572333

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

SPONSORED STORIES